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Case series
Concurrent hysterectomy and bilateral salpingo-oophorectomy during
cytoreductive surgery and hyperthermic intraperitoneal chemotherapy for
non-gynecologic cancers
McKayla J. Riggsa, Miranda Linb, Joseph Kimb, Prakash Pandalaib, Charles S. Dietrich IIIa,⁎
a Division of Gynecologic Oncology, University of Kentucky, 800 Rose Street, Lexington, KY 40536, United States
bDivision of Surgical Oncology, University of Kentucky, 800 Rose Street, Lexington, KY 40536, United States
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A B S T R A C T
Hyperthermic intraperitoneal chemotherapy (HIPEC) is a key component of treatment in non-gynecologic
peritoneal surface malignancies. As many as 10–15% of patients with a gastrointestinal primary malignancy will
present with carcinomatosis. Maximal cytoreductive surgery directly affects the prognosis of patients. The
routine inclusion of hysterectomy with bilateral salpingo-oophorectomy during these procedures optimizes
cytoreduction despite negative pre-operative imaging and findings at the time of surgery. In this case series, we
review twenty non-gynecologic cancer patients who underwent cytoreductive surgery with concurrent hyster-
ectomy and bilateral salpingo-oophorectomy and HIPEC at our institution.
1. Introduction
Cytoreductive surgery (CRS) and hyperthermic intraperitoneal
chemotherapy (HIPEC) are effective treatment modalities for non-gy-
necologic peritoneal surface malignancies. Peritoneal carcinomatosis is
present in 10–30% of patients with gastrointestinal cancer at the time of
initial surgery and usually is associated with a poor prognosis (Harmon
and Sugarbaker, 2005). The goal of HIPEC is to target remaining mi-
croscopic residual tumor following an optimal complete resection. In
the last decade, randomized clinical trials have demonstrated sig-
nificant improved overall survival in patients with gastric cancer who
underwent CRS followed by HIPEC compared to cytoreduction or sys-
temic therapy alone (Yang et al., 2011; Rudloff et al., 2014). Although
utilizing HIPEC for the treatment of colorectal cancer remains con-
troversial, the highest median overall survival to date was seen in a
recent multicenter clinical trial of metastatic colorectal cancer patients
after treatment with CRS and HIPEC of 41.7 months (Quenet and Roca,
2018). CRS and HIPEC have also shown clinical benefit for patients
with peritoneal carcinomatosis originating from the appendix (El
Halabi et al., 2012) and malignant peritoneal mesothelioma (Turaga
et al., 2017). It remains as the only potential cure for patients with
pseudomyxoma peritonei (Benhaim et al., 2019). CRS improved both
overall survival and progression free survival in colon cancers meta-
static to the ovaries. Although statistical significance was not reached in
breast or gastric cancer with ovarian metastasis, a trend towards
improved benefit was noted (Ayhan et al., 2005).
Both intraoperative and postoperative disease burden predicts
overall survival. The Peritoneal Cancer Index (PCI) quantifies disease
burden according to amount and location using intraoperative direct
visualization. Higher PCI values are associated with decreased survival
following CRS and HIPEC (Chu et al., 1989). To evaluate the extent of
surgical debulking, Glehen and Gilly created the CC score that defines
residual tumor diameter: no visible residual tumor (CC-0), less than
2.5 mm (CC-1), 2.5 mm to 2.5 cm (CC-2), and greater than 2.5 cm (CC-
3). Their studies indicated that the benefits of HIPEC diminished as the
CC score increased, and CC score was the most significant independent
prognostic factor for patient survival (Glehen et al., 2004). As expected,
patients undergoing incomplete cytoreduction faced increased mor-
bidity with poorer survival (Lee et al., 2020).
Our institution takes a unique approach to patients with non-gy-
necologic peritoneal carcinomatosis. Female patients deemed optimal
candidates for CRS and HIPEC undergo pre-operative counseling with
both surgical oncology and gynecologic oncology. Using a shared de-
cision-making model with the patient, hysterectomy and bilateral sal-
pingo-oophorectomy are recommended as part of the cytoreductive
effort regardless of whether gynecologic organ involvement is sus-
pected preoperatively. To date, no literature has examined the role for
concurrent hysterectomy and bilateral salpingo-oophorectomy in these
non-gynecologic peritoneal carcinomatosis patients undergoing HIPEC.
In this case series, we describe the demographics, pre-operative,
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intraoperative, and final pathology findings, the operative times, and
immediate postoperative outcomes at our institution.
2. Methods
A retrospective chart review was performed on twenty consecutive
patients presenting to the Markey Cancer Center between August 1,
2018, and February 28, 2020, who underwent cytoreductive surgery
with concurrent hysterectomy and bilateral salpingo-oophorectomy
and HIPEC for a non-gynecologic malignancy at the University of
Kentucky. This review was conducted in accordance with the US
Common Rule and approved by the Institutional Review Board (IRB).
Demographic variables, such as age, race, BMI, preoperative assess-
ment, intraoperative findings, final pathologic diagnosis, and 30-day
surgical outcomes were included in the analysis.
Our institution utilizes an open approach to CRS through a midline
laparotomy incision. Initial exploration quantifies PCI. All female pa-
tients, regardless of gross disease, undergo the following procedures:
resection of the greater and lesser omentum, appendectomy, cholecys-
tectomy, hysterectomy, bilateral salpingo-oophorectomy, and tumor
debulking with the goal of achieving complete resection of all visible
disease. A closed system technique is used for administration of HIPEC
with the Genesis Medical System. The abdomen is warmed with hy-
perthermic saline to 43 °C and chemotherapy is infused and perfused
for 30–90 min with simultaneous agitation of the abdomen. We typi-
cally administer cisplatin for 60 min for gastric cancer and mitomycin C
for 90 min in appendiceal and colorectal primaries. Following admin-
istration, the abdomen is rinsed with three liters of saline, the abdomen
re-opened and irrigated, and the definitive visceral reconstruction
performed (Riggs et al., 2020).
3. Results
The cohort was comprised of twenty female patients aged
18–75 years old (mean 52 years). Reflective of Kentucky demographics,
race was predominantly Caucasian (15/20, 75%). The most common
cancer type was mucinous appendiceal adenocarcinoma (9/20, 45%).
Several of the mucinous appendiceal subtypes were considered low-
grade appendiceal neoplasms (4/9, 44.4%). BMI ranged from
17.3–49.2 kg/m2 (mean 30.24 kg/m2). Demographic characteristics of
all subjects are shown in Table 1.
Nine patients (9/20, 45%) had evidence of gynecologic organ dis-
ease on pre-operative assessment, either from imaging studies with
positron emission tomography (PET) or computed tomography (CT)
scan or from pre-operative assessment via diagnostic laparoscopy to
determine eligibility for HIPEC. Thirteen patients (13/20, 65%) had
gross involvement of the gynecologic organs at the time of surgery, and
sixteen (16/20, 80%) had confirmation of disease on final pathology. Of
the eleven patients with negative pre-operative assessment, five had
gross visible disease at the time of surgery with positive final pathologic
analysis. An additional three had microscopic disease on final pa-
thology that was not visible preoperatively or intraoperatively as shown
in Fig. 1.
The average PCI of the cases was 7.9 with seven patients having a
PCI ≥ 10. At the completion of surgery, eighteen patients (90%) had a
CC-0 score, and two patients (10%) had a score of CC-1 at the time of
HIPEC. Mean estimated blood loss was 152.5 mL (range 50–500 mL) for
the non-gynecologic portion and 106.5 mL (range 25–400 mL) for the
gynecologic portion of the cases. These findings are displayed in
Table 2. The mean operative time of the cases was 481 min (range
271–790 min). Patients were discharged home after a mean of 7 days
(range 4–16 days).
Complications are summarized using the Clavien-Dindo
Classification system in Table 3 (Clavien et al., 2009). One in-
traoperative cystotomy occurred during the completion of the hyster-
ectomy as part of the oncologic resection for her disease burden and is
not included in the graded complications. This patient had recurrent
pseudomyxoma peritonei that had fistulized into the uterus. No other
intraoperative complications were noted.
In the peri- and post-operative course, nine patients (45%) re-
covered uneventfully. Most of the complications recorded were grade I-
II. Five patients had grade III complications, and one had a grade IV
complication. One patient who had extensive diaphragmatic resection
required a chest tube on postoperative day two for a pneumothorax
occurrence. One patient developed pancytopenia felt to be secondary to
sequestered chemotherapy perfusate fluid in the pleural cavity that
resolved after interventional radiology guided thoracentesis and growth
factor support. One patient was noted to have a small pleural effusion
postoperatively that was expectantly managed and later developed a
right upper quadrant hematoma requiring aspiration but never required
a transfusion. The two other grade III complications are described
further with their readmissions. The grade IV complication occurred in
a patient who developed pneumonia following an aspiration event on
postoperative day four requiring ICU care and intubation, resulting in a
sixteen-day postoperative hospital stay.
In the subsequent six-week period following discharge from the
initial hospitalization, four patients required readmission. One patient
was readmitted with dehydration from high colostomy output. Another
patient was readmitted three weeks postoperatively with a peri-splenic
abscess that resolved with drain placement. A third patient was found
to have a strangulated hernia three weeks postoperatively and under-
went an exploratory laparotomy with mesh repair. The final patient was
readmitted three weeks postoperatively for a paralytic ileus treated
expectantly and a pelvic fluid collection managed with antibiotics.
4. Discussion
This descriptive case series examines the potential to maximize
cytoreductive surgery efforts for non-gynecologic cancers undergoing
HIPEC by including a gynecologic oncologist for a planned hyster-
ectomy and bilateral salpingo-oophorectomy, regardless of pre-
operative imaging or intraoperative findings at the time of surgery.
Overall, eighty percent of patients in our series had metastasis to gy-
necologic organs. Even in patients with a negative preoperative as-
sessment for gynecologic involvement, 72.7% (8 of 11 patients) were
Table 1
Demographic Characteristics.
Characteristics No. Patients (%)
Total 20 (100)
Age Group Range (18–75 years)
< 52 years 8 (40.0)
52+ years 12 (60.0)
Race
Caucasian 15 (75.0)
African American 2 (10.0)
Other 3 (15.0)
Cancer Type
Mucinous Appendiceal 9 (45.0)
Colonic Adenocarcinoma 3 (15.0)
Gastric Adenocarcinoma 3 (15.0)
Urachal Mucinous 1 (5.0)
Mesothelioma 2 (10.0)
Small Bowel Adenocarcinoma 2 (10.0)
Pathologic Grade
1 5 (25.0)
2 6 (30.0)
3 3 (15.0)
Unknown 6 (30.0)
BMI (kg/m2)
15–25 6 (30.0)
26–35 7 (35.0)
36–45 6 (5.61)
46–55 1 (5.0)
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confirmed to have either gross disease intraoperatively or microscopic
disease on final pathology. This suggests that by not including a
planned hysterectomy or bilateral salpingo-oophorectomy at the time of
surgery, a less optimal debulking may occur. In addition, by involving
the gynecologic oncology service in preoperative assessment, patients
were counseled about the risks and benefits of a total hysterectomy and
bilateral salpingo-oophorectomy before the procedure and were
mentally prepared to undergo that portion of the surgery.
In non-gynecologic cancers, HIPEC and CRS have an estimated
morbidity of 30–50%, mortality of 1–5%, with a mean operative time of
388–550 min depending on the extent of peritoneal procedures (Baratti
et al., 2010). A positive correlation between duration of surgery,
number of peritonectomy procedures and resections, and number of
suture lines correlated with combined grade III-IV morbidities. Dura-
tion of surgery was the most common predictor of morbidity and was
associated with pancreatitis, cardiovascular toxicity, wound sepsis,
systemic sepsis, bile leak, and deep vein thrombosis. In a study by
Stephens, et al., their average patient had 2.1 prior surgeries and a PCI
of 19 with the majority (150/183) having appendiceal primary as the
source (Stephens et al., 1999).
In our patients, mean operative time including the hysterectomy
and bilateral salpingo-oophorectomy was 481 min, which is similar to
that quoted in prior studies. Our perioperative and postoperative
complications are also similar to what is quoted in the literature, sug-
gesting that the addition of a planned hysterectomy and bilateral sal-
pingo-oophorectomy with each case may not add to the overall mor-
bidity of the procedure. The inclusion of a hysterectomy added an
average of 106 mL of blood loss to the case. The only event directly
linked to hysterectomy in our series was a cystotomy created during en
bloc resection of the uterus with tumor that was not unexpected given
her disease extent and required oncologic resection. A second patient
requiring readmission three weeks postoperatively for ileus was found
to have a pelvic fluid collection requiring antibiotics that could have
been secondary to the hysterectomy portion of the case. Our patients
had an average PCI of 7.9 with seven of twenty patients having a
PCI ≥ 10. The PCI of the patients in the prior studies mentioned was
19, suggesting a higher surgical complexity, although this does not take
into consideration the surgical and medical history of our patients prior
to the operation.
The key limitation to this study is its retrospective nature and case
series design. Based on our practice approach, a control group that did
not have concurrent hysterectomy and bilateral salpingo-oophorectomy
is unavailable for comparison of outcomes. However, this is the first
study to take a deeper look into concurrent hysterectomy and bilateral
salpingo-oophorectomy in non-gynecologic cancer cases. Eighty per-
cent of patients in our series had gynecologic organ involvement in-
cluding both expected and unexpected final pathologic findings. Prior
studies would suggest that maximal cytoreduction leads to improved
outcomes, but further prospective trials would be needed to fully un-
derstand the survival impact of hysterectomy and bilateral salpingo-
oophorectomy in this setting.
Fig. 1. Pelvic organ involvement by non-gynecologic malignancies flowsheet.
Table 2
Surgical Demographics.
Characteristics No. Patients (%)
Total 20 (100)
PCI values
Range (mean) 0–22 (7.9)
Cytoreduction Score
CC-0 18 (90)
CC-1 2 (10)
Operative Time
Range (mean), minutes 318–790 (481.45)
Estimated blood loss, average in cc (range)
Gynecologic 106.5 (25–400 mL)
Non-gynecologic 152.5 (50–500 mL)
Length of hospital stay
Range (mean), days 4–16 (7.4)
Table 3
Morbidity after surgical cytoreduction and HIPEC.
Morbidity Grade Total (%)
I-II III IV
Gastrointestinal tract 3 (15.0)
Paralytic ileus 2 – –
Anastomotic leak – – –
Strangulated hernia – 1 –
Hematologic 5 (25.0)
Blood transfusion 2 – –
Wound hematoma – 1 –
Leukopenia requiring intervention 2 – –
Infections 3 (15.0)
Superficial wound infection 1 – –
Deep surgical site 1 1 –
Pulmonary 4 (20.0)
Pleural effusions 1 1 –
Pneumothorax – 1 –
Aspiration pneumonia – – 1
Renal 2 (10.0)
Acute Kidney Injury 2 – –
Hospital Readmissions
Readmission < 30 days 4 (20.0)
Readmission > 30–90 days 0 (0.0)
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5. Conclusion
CRS and HIPEC are treatment options for patients with non-gyne-
cologic cancers, and survival outcomes have been correlated with the
extent of CRS. Our experience at Markey Cancer Center suggests a
benefit to concurrent hysterectomy and bilateral salpingo-oophor-
ectomy as part of the cytoreductive effort in these cases. Twenty-five
percent (5/20) of patients had gross involvement of gynecologic organs
at the time of surgery that was unanticipated based on preoperative
evaluation. An additional fifteen percent (3/20) of our patients had
microscopic involvement that was unexpected given both pre- and in-
traoperative assessment. Involving a gynecologic oncologist in the care
of these patients preoperatively allows for additional counseling and
patient preparation. Our morbidity and operative times are within the
reported range of prior literature, even with our inclusion of a hyster-
ectomy and bilateral salpingo-oophorectomy at the time of CRS. We feel
there is benefit in a multidisciplinary approach to these patients and
that concurrent hysterectomy and bilateral salpingo-oophorectomy at
the time of CRS and HIPEC may maximize the CRS without adding
significant surgical morbidity.
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